In this context, only a comparative study conducted on the efficacy of lapatinib, a tyrosine kinase inhibitor reports how HER2 expression impacts the Raman fingerprint in triple negative or HER2 + BC cell lines [20, 48]. The gene discussed is ERBB2; the disease is breast cancer.